Decision: Favourable
Study Title:
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) c
NREC Code:
22-NREC-CT-169
Decision:
Favourable
Meeting Date:
09/11/2022
Study Type:
CT Application
Principal Investigator:
Dr Maeve Crowley
PI Institution:
Cork University Hospital
Sponsor:
Anthos Therapeutics Inc.